MedTech Spectrum

Article Name Regulatory

Compliance To Competitive Advantage: The New Performance Playbook For Medical Device Manufacturing

As QMSR, EUDAMED, cybersecurity, and AI controls widen the compliance surface, leading manufacturers are converting the same pressures into measurable gains in quality, delivery, cost, and speed through digitally fluent teams, auditable AI, resilient supply networks, and data centric regulatory operations.

19th February, 2026

Everest Medicines Announces China NMPA Approval of VELSIPITY(R) for Adults

The approval was based on results from the Asian multicenter Phase 3 ENLIGHT UC study (ES101002) and the global ELEVATE UC Phase 3 program (ELEVATE UC 52 and ELEVATE UC 12)

09th February, 2026

Army’s Surgical Eye Camp Restores Vision for Veterans, Locals in Bhuj

The initiative reflects the Indian Army’s continued commitment to veterans’ welfare and community healthcare, particularly in geographically remote and strategically significant areas

04th February, 2026

Healthcare Leaders Applaud Budget 2026 Focus on Access, Infrastructure and Prevention

Highlighting its focus on healthcare infrastructure, medical tourism, affordable medicines and the expansion of AYUSH

02nd February, 2026

Union Budget 2026 Wins Healthcare Experts’ Support for Focus on Prevention, Affordability and Capacity Building

Key measures such as the creation of five medical value tourism hubs, the Biotech SHAKTI initiative, expansion of biopharma manufacturing, and training of 1.5 lakh caregivers

01st February, 2026

Union Budget 2026 Signals Strong Push for Innovation-Driven, Inclusive Healthcare Ecosystem

Industry leaders and healthcare professionals have broadly welcomed the measures

01st February, 2026

India Central Budget 2026 Sets Up Regional Medical Hubs And Expands Ayush And Allied Health Training

Union Finance Minister Nirmala Sitharaman announced in the Budget

01st February, 2026

India Central Budget 2026 Positions Healthcare As A Core Growth Driver

Union Finance Minister Nirmala Sitharaman announced in the Budget

01st February, 2026

Indian Union Budget 2026 Focuses On Affordable Diabetes And Cancer Treatment Through BioPharma Shakti

Union Finance Minister Nirmala Sitharaman announced in the Budget

01st February, 2026

2025 Biological Device Application Approvals. How FDA Clearances Are Reshaping Blood Banking, Diagnostics, and Point of Care Medicine

From blood bank software and immunohematology analysers, to HIV diagnostics and platelet rich plasma systems, the 2025 approval landscape signals a clear shift towards automation, safety, traceability, and point of care innovation across transfusion and laboratory medicine

26th December, 2025

ALC Pune Launches CRE-2025 to Advance Amputee Rehabilitation in India

CRE-2025 aims to advance holistic amputee care and strengthen India’s rehabilitation landscape through structured training, knowledge exchange, and innovation

11th December, 2025

Axogen Announces FDA Approval of Biologics License Application for AVANCE

Avance is an acellular nerve scaffold for the treatment of adult and pediatric patients aged 1 month or older with sensory, mixed, and motor peripheral nerve discontinuities

04th December, 2025

Olympus Initiates Global Removal of ViziShot 2 FLEX Needles Following Safety Reports

The voluntary action affects devices manufactured before May 12, 2025, after reports of component detachment linked to patient injuries and one death, with Olympus reinforcing safeguards to prioritise patient safety.

23rd September, 2025

Techsomed Secures FDA 510(k) Clearance for BioTraceIO360 Kidney Ablation Indication

The expanded clearance extends BioTraceIO360 beyond liver applications to kidney procedures, advancing Techsomed’s vision of a multi-organ, AI-driven image-guided therapy platform that standardises minimally invasive cancer care.

23rd September, 2025

Tasso-SNBL Secures Japanese Certification for Self-Collection Blood Kit

Breakthrough approval supports home-based testing and strengthens access to care

10th September, 2025

Abbott’s Navitor™ Wins CE Mark Expansion, Offering Minimally Invasive Valve Replacement to Low- and Intermediate-Risk Patients in Europe

Backed by VANTAGE trial data unveiled at ESC Congress 2025 and published in JACC: Cardiovascular Interventions, Navitor now covers all surgical risk categories—while new ESC/EACTS guidelines also strengthen support for MitraClip™ and TriClip™ in mitral and tricuspid valve disease management.

01st September, 2025